• Enveric Biosciences reported new preclinical data supporting a non-hallucinogenic profile for lead neuroplastogenic candidate EB-003.
• A GloSensor cAMP assay showed EB-003 in a non-hallucinogenic signaling range versus reference compounds, consistent with reported 5-HT2A Gi markers.
• Results aligned with previously disclosed BRET assay findings, strengthening cross-platform evidence ahead of planned Phase 1 first-in-human development.
• The company positioned a non-hallucinogenic profile as a potential path to more conventional blinded trials and simpler outpatient use if replicated in humans.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608050800BIZWIRE_USPR_____20260805_BW599685) on August 05, 2026, and is solely responsible for the information contained therein.